135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S154-

  Oxnard, G R ^a   Thress, K S ^b   Alden, R S ^a   Lawrance, R ^b   Paweletz, C P ^a   Cantarini, M ^b   Barrett, C ^b   Yang, J ^c   Janne P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OSIMERTINIB;

ADVANCED CANCER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; EGFR GENE; FALSE NEGATIVE RESULT; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 85015248073     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30328-8     Document Type: Article

References (0)